JAC Advance Access published online on May 5, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh248
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratory Specialists,
Inc., Cleveland, OH;
* To whom correspondence should be addressed. E-mail: amdlmk{at}aol.com.
In vitro susceptibility data were
collected for co-amoxiclav and other antimicrobial agents against
1297 recent anaerobe isolates collected in Europe and the USA. The
co-amoxiclav (amoxicillin/clavulanic acid) MIC50/90s
(amoxicillin/clavulanic acid concentration in a ratio of 2:1, expressed
in terms of amoxicillin concentration in mg/L) were 0.5/4 for Bacteroides fragilis,
Revised March 12, 2004
Accepted March 22, 2004
Original article
Surveillance of susceptibility patterns in 1297
European and US anaerobic and capnophilic isolates to co-amoxiclav
and five other antimicrobial agents
2 M.
S. Hershey Medical Center, Hershey, PA;
3 R. M. Alden Research Laboratory, Santa Monica,
CA, USA;
4 Institute für
Medizinische Mikrobiologie und Infektionsepidemiologie der Universität
Leipzig, Leipzig, Germany;
5 ADRINORD,
Lille, France
Abstract 
0.125/1
for Prevotella species, 0.125/0.25
for Fusobacterium nucleatum, 0.5/1
for Eikenella corrodens, 0.25/8 for Peptostreptococcus
anaerobius, 0.125/0.5 for Micromonas (Peptostreptococcus) micros, 0.25/0.5 for Fingoldia (Peptostreptococcus) magna, and 0.125/0.125 for Porphyromonas species.
The co-amoxiclav susceptibility rate for B. fragilis was 94.6%,
for P. anaerobius 84.3% and for all other
species tested 100%. These data indicate that co-amoxiclav remains
an effective drug for the antimicrobial treatment and prophylaxis
of many anaerobic infections. Among the comparator drugs, metronidazole
was very active against all bacterial species (>96% susceptible) except E. corrodens (MIC50/90 of >32/>64
mg/L), which is a capnophilic organism. Imipenem was also highly active
against all species (>98% susceptible). Levofloxacin
and clindamycin were the least potent agents tested, particularly
against Bacteroides, Prevotella and Peptostreptococcus (levofloxacin
susceptibility rates: Bacteroides 72.7%, Prevotella 71.5%, F. magna 72.4%;
clindamycin susceptibility rates: Bacteroides 79.5%, Prevotella 92.1%, F. magna 84.7%).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-Y. Liu, Y.-T. Huang, C.-H. Liao, L.-C. Yen, H.-Y. Lin, and P.-R. Hsueh Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kononen, A. Bryk, P. Niemi, and A. Kanervo-Nordstrom Antimicrobial Susceptibilities of Peptostreptococcus anaerobius and the Newly Described Peptostreptococcus stomatis Isolated from Various Human Sources Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2205 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-F. Odou, C. Muller, L. Calvet, and L. Dubreuil In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections J. Antimicrob. Chemother., April 1, 2007; 59(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Katsandri, J. Papaparaskevas, A. Pantazatou, G. L. Petrikkos, G. Thomopoulos, D. P. Houhoula, and A. Avlamis Two Cases of Infections Due to Multidrug-Resistant Bacteroides fragilis Group Strains. J. Clin. Microbiol., September 1, 2006; 44(9): 3465 - 3467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Boyanova, R. Kolarov, G. Gergova, E. Deliverska, J. Madjarov, M. Marinov, and I. Mitov Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria. J. Med. Microbiol., September 1, 2006; 55(Pt 9): 1285 - 1289. [Abstract] [Full Text] [PDF]
|
|